University of Missouri School of Medicine scientists explain a potentially new early cancer detection and treatment method using nanoparticles created at MU in an article published in the Proceedings of the National Academy of Sciences. The article illustrates how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung cancers in humans.
"When injected into the body, the Gastrin Releasing Peptide (GRP) cancer receptor serves as a signaling device to the gold nanoparticle, which allows for targeted delivery to the tumor site," said Kattesh Katti, PhD, who wrote the article with Raghuraman Kannan, PhD.
Katti, Kannan, and others with the MU School of Medicine Department of Radiology have been researching the development of tumor specific gold nanoparticles for more than five years.
"This discovery presents a plethora of realistic opportunities for clinical translation, not only in the development of nanomedicine-based diagnostic technologies for early stage detection but also for therapies for treating tumors in prostate, breast and small cell lung cancer," Kannan said.
Kannan and Katti have developed a library of more than 85 engineered nanoparticles for use in molecular imaging and therapy. With scientists at the MU Research Reactor (MURR), the most powerful university reactor in the world, they have developed cancer specific therapeutic radioactive gold nanoparticles. MURR is one of only a few sites worldwide able to produce cancer targeting gold nanoparticles. ###
In 2005, Katti received a prostate cancer research grant that distinguished MU as one of only 12 universities to participate in the National Cancer Institute's national nanotechnology platform partnership. The grant supported MU faculty members in radiology, MURR, veterinary medicine, chemistry, physics and other programs to collaborate in establishing MU as a leader in advancing nanomedicine for the early detection and treatment of cancer.
In addition to serving as director of MU's Cancer Nanotechnology Platform, Katti is a Curators' Distinguished Professor in Radiology and Physics and Margaret Proctor Mulligan Distinguished Professor in Medical Research. Kannan is the Michael J. and Sharon R. Bukstein Distinguished Faculty Scholar in Cancer Research.
The article, titled "Bombesin Functionalized Gold Nanoparticles Show In vitro and In vivo Cancer Receptor Specificity," is available online at: www.pnas.org/content/early/abstract
The Proceedings of the National Academy of Sciences of the United States of America is one of the world's most-cited multidisciplinary scientific serials. Since its establishment in 1914, it continues to publish cutting-edge research reports, commentaries, reviews, perspectives, colloquium papers, and actions of the academy.
Contact: Laura Gerding GerdingLA@health.missouri.edu 573-882-9193 University of Missouri-Columbia